Synthesis of siRNA nanoparticles to silence plaque-destabilizing gene in atherosclerotic lesional macrophages.
Journal
Nature protocols
ISSN: 1750-2799
Titre abrégé: Nat Protoc
Pays: England
ID NLM: 101284307
Informations de publication
Date de publication:
03 2022
03 2022
Historique:
received:
31
05
2021
accepted:
15
11
2021
pubmed:
6
2
2022
medline:
8
4
2022
entrez:
5
2
2022
Statut:
ppublish
Résumé
Macrophages in atherosclerotic lesions promote plaque progression and are an attractive therapeutic target in cardiovascular research. Here we present a protocol for synthesis of small interfering RNA (siRNA) nanoparticles (NP) that target lesional macrophages as a potential treatment for atherosclerosis. Ca
Identifiants
pubmed: 35121853
doi: 10.1038/s41596-021-00665-4
pii: 10.1038/s41596-021-00665-4
pmc: PMC9734002
mid: NIHMS1851913
doi:
Substances chimiques
RNA, Small Interfering
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
748-780Subventions
Organisme : NHLBI NIH HHS
ID : P01 HL087123
Pays : United States
Organisme : NHLBI NIH HHS
ID : R00 HL145131
Pays : United States
Organisme : NHLBI NIH HHS
ID : R01 HL127464
Pays : United States
Organisme : NHLBI NIH HHS
ID : R35 HL145228
Pays : United States
Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Nature Limited.
Références
Schultze, J. L., Schmieder, A. & Goerdt, S. Macrophage activation in human diseases. Semin. Immunol. 27, 249–256 (2015).
pubmed: 26303100
doi: 10.1016/j.smim.2015.07.003
Moore, K. J. & Tabas, I. Macrophages in the pathogenesis of atherosclerosis. Cell 145, 341–355 (2011).
pubmed: 21529710
pmcid: 3111065
doi: 10.1016/j.cell.2011.04.005
Ross, R. Atherosclerosis—an inflammatory disease. N. Engl. J. Med. 340, 115–126 (1999).
pubmed: 9887164
doi: 10.1056/NEJM199901143400207
Kuznetsova, T., Prange, K. H. M., Glass, C. K. & de Winther, M. P. J. Transcriptional and epigenetic regulation of macrophages in atherosclerosis. Nat. Rev. Cardiol. 17, 216–228 (2020).
pubmed: 31578516
doi: 10.1038/s41569-019-0265-3
Huang, X. et al. Intercalation-driven formation of siRNA nanogels for cancer therapy. Nano Lett. 21, 9706–9714 (2021).
pubmed: 34723546
doi: 10.1021/acs.nanolett.1c03539
Zhu, X. et al. Long-circulating siRNA nanoparticles for validating Prohibitin1-targeted non-small cell lung cancer treatment. Proc. Natl Acad. Sci. USA 112, 7779–7784 (2015).
pubmed: 26056316
pmcid: 4485147
doi: 10.1073/pnas.1505629112
Davidson, B. L. & McCray, P. B. Current prospects for RNA interference-based therapies. Nat. Rev. Genet. 12, 329–340 (2011).
pubmed: 21499294
pmcid: 7097665
doi: 10.1038/nrg2968
Whitehead, K. A., Langer, R. & Anderson, D. G. Knocking down barriers: advances in siRNA delivery. Nat. Rev. Drug Discov. 8, 129–138 (2009).
pubmed: 19180106
pmcid: 7097568
doi: 10.1038/nrd2742
Castanotto, D. & Rossi, J. J. The promises and pitfalls of RNA-interference-based therapeutics. Nature 457, 426–433 (2009).
pubmed: 19158789
pmcid: 2702667
doi: 10.1038/nature07758
Chen, J. et al. Synthesis and use of an amphiphilic dendrimer for siRNA delivery into primary immune cells. Nat. Protoc. 16, 327–351 (2021).
pubmed: 33277630
doi: 10.1038/s41596-020-00418-9
Loynachan, C. N. et al. Renal clearable catalytic gold nanoclusters for in vivo disease monitoring. Nat. Nanotechnol. 14, 883–890 (2019).
pubmed: 31477801
pmcid: 7045344
doi: 10.1038/s41565-019-0527-6
Terrazas, M. & Kool, E. T. RNA major groove modifications improve siRNA stability and biological activity. Nucleic Acids Res. 37, 346–353 (2008).
pubmed: 19042976
pmcid: 2632910
doi: 10.1093/nar/gkn958
Sioud, M., Furset, G. & Cekaite, L. Suppression of immunostimulatory siRNA-driven innate immune activation by 2′-modified RNAs. Biochem. Biophys. Res. Commun. 361, 122–126 (2007).
pubmed: 17658482
doi: 10.1016/j.bbrc.2007.06.177
Choung, S., Kim, Y. J., Kim, S., Park, H.-O. & Choi, Y.-C. Chemical modification of siRNAs to improve serum stability without loss of efficacy. Biochem. Biophys. Res. Commun. 342, 919–927 (2006).
pubmed: 16598842
doi: 10.1016/j.bbrc.2006.02.049
Kanasty, R., Dorkin, J. R., Vegas, A. & Anderson, D. Delivery materials for siRNA therapeutics. Nat. Mater. 12, 967–977 (2013).
pubmed: 24150415
doi: 10.1038/nmat3765
Yin, H. et al. Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 15, 541–555 (2014).
pubmed: 25022906
doi: 10.1038/nrg3763
Mullard, A. FDA approves landmark RNAi drug. Nat. Rev. Drug Discov. 17, 613–614 (2018).
pubmed: 30160256
Frank-Kamenetsky, M. et al. Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc. Natl Acad. Sci. USA 105, 11915–11920 (2008).
pubmed: 18695239
pmcid: 2575310
doi: 10.1073/pnas.0805434105
Zimmermann, T. S. et al. RNAi-mediated gene silencing in non-human primates. Nature 441, 111–114 (2006).
pubmed: 16565705
doi: 10.1038/nature04688
Tadin-Strapps, M. et al. siRNA-induced liver ApoB knockdown lowers serum LDL-cholesterol in a mouse model with human-like serum lipids. J. Lipid Res. 52, 1084–1097 (2011).
pubmed: 21398511
pmcid: 3090230
doi: 10.1194/jlr.M012872
Pan, H. et al. Anti-JNK2 peptide–siRNA nanostructures improve plaque endothelium and reduce thrombotic risk in atherosclerotic mice. Int. J. Nanomed. 13, 5187 (2018).
doi: 10.2147/IJN.S168556
Flores, A. M. et al. Nanoparticle therapy for vascular diseases. Arterioscler. Thromb. Vasc. Biol. 39, 635–646 (2019).
pubmed: 30786744
pmcid: 6436996
doi: 10.1161/ATVBAHA.118.311569
Sager, H. B. et al. RNAi targeting multiple cell adhesion molecules reduces immune cell recruitment and vascular inflammation after myocardial infarction. Sci. Transl. Med. 8, 342ra380–342ra380 (2016).
doi: 10.1126/scitranslmed.aaf1435
Dahlman, J. E. et al. In vivo endothelial siRNA delivery using polymeric nanoparticles with low molecular weight. Nat. Nanotechnol. 9, 648 (2014).
pubmed: 24813696
pmcid: 4207430
doi: 10.1038/nnano.2014.84
Leuschner, F. et al. Therapeutic siRNA silencing in inflammatory monocytes in mice. Nat. Biotechnol. 29, 1005–1010 (2011).
pubmed: 21983520
pmcid: 3212614
doi: 10.1038/nbt.1989
Tao, W. et al. siRNA nanoparticles targeting CaMKIIγ in lesional macrophages improve atherosclerotic plaque stability in mice. Sci. Transl. Med. 12, eaay1063 (2020).
pubmed: 32718990
pmcid: 7476570
doi: 10.1126/scitranslmed.aay1063
Doran, A. C. et al. CAMKIIγ suppresses an efferocytosis pathway in macrophages and promotes atherosclerotic plaque necrosis. J. Clin. Investig. 127, 4075–4089 (2017).
pubmed: 28972541
pmcid: 5663361
doi: 10.1172/JCI94735
Doran, A. C., Yurdagul, A. & Tabas, I. Efferocytosis in health and disease. Nat. Rev. Immunol. 20, 254–267 (2020).
pubmed: 31822793
doi: 10.1038/s41577-019-0240-6
Finn, A. V., Nakano, M., Narula, J., Kolodgie, F. D. & Virmani, R. Concept of vulnerable/unstable plaque. Arterioscler. Thromb. Vasc. Biol. 30, 1282–1292 (2010).
pubmed: 20554950
doi: 10.1161/ATVBAHA.108.179739
Islam, M. A. et al. Restoration of tumour-growth suppression in vivo via systemic nanoparticle-mediated delivery of PTEN mRNA. Nat. Biomed. Eng. 2, 850–864 (2018).
pubmed: 31015614
pmcid: 6486184
doi: 10.1038/s41551-018-0284-0
Kong, N. et al. Synthetic mRNA nanoparticle-mediated restoration of p53 tumor suppressor sensitizes p53-deficient cancers to mTOR inhibition. Sci. Transl. Med. 11, eaaw1565 (2019).
pubmed: 31852795
pmcid: 7024563
doi: 10.1126/scitranslmed.aaw1565
Baden, L. R. et al. Efficacy and safety of the mRNA-1273 SARS-CoV-2 vaccine. N. Engl. J. Med. 384, 403–416 (2021).
pubmed: 33378609
doi: 10.1056/NEJMoa2035389
Polack, F. P. et al. Safety and efficacy of the BNT162b2 mRNA Covid-19 vaccine. N. Engl. J. Med. 383, 2603–2615 (2020).
doi: 10.1056/NEJMoa2034577
Tang, Z. et al. A materials-science perspective on tackling COVID-19. Nat. Rev. Mater. 5, 847–860 (2020).
pubmed: 33078077
pmcid: 7556605
doi: 10.1038/s41578-020-00247-y
Wang, Z. et al. mRNA vaccine-elicited antibodies to SARS-CoV-2 and circulating variants. Nature 592, 616–622 (2021).
pubmed: 33567448
pmcid: 8503938
doi: 10.1038/s41586-021-03324-6
Bradley, T. et al. Antibody responses after a single dose of SARS-CoV-2 mRNA vaccine. N. Engl. J. Med. 384, 1959–1961 (2021).
pubmed: 33755375
doi: 10.1056/NEJMc2102051
Tang, Z. et al. Insights from nanotechnology in COVID-19 treatment. Nano Today 36, 101019 (2021).
pubmed: 33178330
doi: 10.1016/j.nantod.2020.101019
Song, M. S., Salmena, L. & Pandolfi, P. P. The functions and regulation of the PTEN tumour suppressor. Nat. Rev. Mol. Cell Biol. 13, 283–296 (2012).
pubmed: 22473468
doi: 10.1038/nrm3330
Kowalski, P. S., Rudra, A., Miao, L. & Anderson, D. G. Delivering the messenger: advances in technologies for therapeutic mRNA delivery. Mol. Ther. 27, 710–728 (2019).
pubmed: 30846391
pmcid: 6453548
doi: 10.1016/j.ymthe.2019.02.012
Ahmadi, S. et al. Stimulus-responsive sequential release systems for drug and gene delivery. Nano Today 34, 100914 (2020).
pubmed: 32788923
pmcid: 7416836
doi: 10.1016/j.nantod.2020.100914
Liu, Y. & Chen, X. Macrophage-targeted gene therapy to improve the atherosclerotic plaque stability. Matter 3, 621–622 (2020).
doi: 10.1016/j.matt.2020.08.009
Zhao, W., Hou, X., Vick, O. G. & Dong, Y. RNA delivery biomaterials for the treatment of genetic and rare diseases. Biomaterials 217, 119291 (2019).
pubmed: 31255978
pmcid: 6635005
doi: 10.1016/j.biomaterials.2019.119291
Wang, Y. & Yu, C. Emerging concepts of nanobiotechnology in mRNA delivery. Angew. Chem. Int. Ed. 59, 23374–23385 (2020).
doi: 10.1002/anie.202003545
Vaughan, H. J., Green, J. J. & Tzeng, S. Y. Cancer‐targeting nanoparticles for combinatorial nucleic acid delivery. Adv. Mater. 32, 1901081 (2020).
doi: 10.1002/adma.201901081
Zhou, Y. et al. Blood–brain barrier-penetrating siRNA nanomedicine for Alzheimer’s disease therapy. Sci. Adv. 6, eabc7031 (2020).
pubmed: 33036977
pmcid: 7546706
doi: 10.1126/sciadv.abc7031
Truong, N. P. et al. An influenza virus-inspired polymer system for the timed release of siRNA. Nat. Commun. 4, 1902 (2013).
pubmed: 23695696
doi: 10.1038/ncomms2905
Hu, Q., Li, H., Wang, L., Gu, H. & Fan, C. DNA nanotechnology-enabled drug delivery systems. Chem. Rev. 119, 6459–6506 (2019).
pubmed: 29465222
doi: 10.1021/acs.chemrev.7b00663
Hu, Q., Wang, S., Wang, L., Gu, H. & Fan, C. DNA nanostructure-based systems for intelligent delivery of therapeutic oligonucleotides. Adv. Healthc. Mater. 7, 1701153–1701172 (2018).
doi: 10.1002/adhm.201701153
Lee, H. et al. Molecularly self-assembled nucleic acid nanoparticles for targeted in vivo siRNA delivery. Nat. Nanotechnol. 7, 389–393 (2012).
pubmed: 22659608
pmcid: 3898745
doi: 10.1038/nnano.2012.73
Thai, H. B. D. et al. Kidney-targeted cytosolic delivery of siRNA using a small-sized mirror DNA tetrahedron for enhanced potency. ACS Cent. Sci. 6, 2250–2258 (2020).
pubmed: 33376785
pmcid: 7760472
doi: 10.1021/acscentsci.0c00763
Bujold, K. E., Hsu, J. C. C. & Sleiman, H. F. Optimized DNA “nanosuitcases” for encapsulation and conditional release of siRNA. J. Am. Chem. Soc. 138, 14030–14038 (2016).
pubmed: 27700075
doi: 10.1021/jacs.6b08369
Rahman, M. A. et al. Systemic delivery of bc12‐targeting siRNA by DNA nanoparticles suppresses cancer cell growth. Angew. Chem. Int. Ed. 56, 16023–16027 (2017).
doi: 10.1002/anie.201709485
Semple, S. C. et al. Rational design of cationic lipids for siRNA delivery. Nat. Biotechnol. 28, 172–176 (2010).
pubmed: 20081866
doi: 10.1038/nbt.1602
Kulkarni, J. A., Witzigmann, D., Chen, S., Cullis, P. R. & van der Meel, R. Lipid nanoparticle technology for clinical translation of siRNA therapeutics. Acc. Chem. Res. 52, 2435–2444 (2019).
pubmed: 31397996
doi: 10.1021/acs.accounts.9b00368
Whitehead, K. A. et al. Degradable lipid nanoparticles with predictable in vivo siRNA delivery activity. Nat. Commun. 5, 4277 (2014).
pubmed: 24969323
doi: 10.1038/ncomms5277
Wittrup, A. et al. Visualizing lipid-formulated siRNA release from endosomes and target gene knockdown. Nat. Biotechnol. 33, 870–876 (2015).
pubmed: 26192320
pmcid: 4663660
doi: 10.1038/nbt.3298
Sahay, G. et al. Efficiency of siRNA delivery by lipid nanoparticles is limited by endocytic recycling. Nat. Biotechnol. 31, 653–658 (2013).
pubmed: 23792629
pmcid: 3814166
doi: 10.1038/nbt.2614
Liu, S. et al. Membrane-destabilizing ionizable phospholipids for organ-selective mRNA delivery and CRISPR–Cas gene editing. Nat. Mater. 20, 701–710 (2021).
pubmed: 33542471
pmcid: 8188687
doi: 10.1038/s41563-020-00886-0
Cheng, Q. et al. Selective organ targeting (SORT) nanoparticles for tissue-specific mRNA delivery and CRISPR–Cas gene editing. Nat. Nanotechnol. 15, 313–320 (2020).
pubmed: 32251383
pmcid: 7735425
doi: 10.1038/s41565-020-0669-6
Xu, X. et al. Enhancing tumor cell response to chemotherapy through nanoparticle-mediated codelivery of siRNA and cisplatin prodrug. Proc. Natl Acad. Sci. USA 110, 18638–18643 (2013).
pubmed: 24167294
pmcid: 3832000
doi: 10.1073/pnas.1303958110
Wilson, D. S. et al. Orally delivered thioketal nanoparticles loaded with TNF-α–siRNA target inflammation and inhibit gene expression in the intestines. Nat. Mater. 9, 923–928 (2010).
pubmed: 20935658
pmcid: 3142359
doi: 10.1038/nmat2859
Díez, S., Miguéliz, I. & De Ilarduya, C. T. Targeted cationic poly (D, L-lactic-co-glycolic acid) nanoparticles for gene delivery to cultured cells. Cell. Mol. Biol. Lett. 14, 347–362 (2009).
pubmed: 19194666
pmcid: 6275944
doi: 10.2478/s11658-009-0003-7
Shi, J., Xiao, Z., Votruba, A. R., Vilos, C. & Farokhzad, O. C. Differentially charged hollow core/shell lipid–polymer–lipid hybrid nanoparticles for small interfering RNA delivery. Angew. Chem. Int. Ed. 50, 7027–7031 (2011).
doi: 10.1002/anie.201101554
Mui, B. L. et al. Influence of polyethylene glycol lipid desorption rates on pharmacokinetics and pharmacodynamics of siRNA lipid nanoparticles. Mol. Ther. Nucleic Acids 2, e139 (2013).
pubmed: 24345865
pmcid: 3894582
doi: 10.1038/mtna.2013.66
Love, K. T. et al. Lipid-like materials for low-dose, in vivo gene silencing. Proc. Natl Acad. Sci. USA 107, 1864–1869 (2010).
pubmed: 20080679
pmcid: 2804742
doi: 10.1073/pnas.0910603106
Schöttler, S. et al. Protein adsorption is required for stealth effect of poly(ethylene glycol)- and poly(phosphoester)-coated nanocarriers. Nat. Nanotechnol. 11, 372–377 (2016).
pubmed: 26878141
doi: 10.1038/nnano.2015.330
Petros, R. A. & DeSimone, J. M. Strategies in the design of nanoparticles for therapeutic applications. Nat. Rev. Drug Discov. 9, 615–627 (2010).
pubmed: 20616808
doi: 10.1038/nrd2591
Moghimi, S. M., Hunter, A. C. & Murray, J. C. Long-circulating and target-specific nanoparticles: theory to practice. Pharmacol. Rev. 53, 283–318 (2001).
pubmed: 11356986
Gilleron, J. et al. Image-based analysis of lipid nanoparticle–mediated siRNA delivery, intracellular trafficking and endosomal escape. Nat. Biotechnol. 31, 638 (2013).
pubmed: 23792630
doi: 10.1038/nbt.2612
Ahmed, S. A., Gogal, R. M. Jr & Walsh, J. E. A new rapid and simple non-radioactive assay to monitor and determine the proliferation of lymphocytes: an alternative to [3H] thymidine incorporation assay. J. Immunol. Methods 170, 211–224 (1994).
pubmed: 8157999
doi: 10.1016/0022-1759(94)90396-4
Miller, L. R. et al. Considering sex as a biological variable in preclinical research. FASEB J. 31, 29–34 (2017).
pubmed: 27682203
doi: 10.1096/fj.201600781r
Fredman, G. et al. Targeted nanoparticles containing the proresolving peptide Ac2-26 protect against advanced atherosclerosis in hypercholesterolemic mice. Sci. Transl. Med. 7, 275ra220–275ra220 (2015).
doi: 10.1126/scitranslmed.aaa1065
Zhu, X. et al. Surface de-PEGylation controls nanoparticle-mediated sirna delivery in vitro and in vivo. Theranostics 7, 1990–2002 (2017).
pubmed: 28638484
pmcid: 5479285
doi: 10.7150/thno.18136
Liu, J. et al. Fast and efficient CRISPR/Cas9 genome editing in vivo enabled by bioreducible lipid and messenger RNA nanoparticles. Adv. Mater. 31, 1902575 (2019).
doi: 10.1002/adma.201902575
Ensuring accurate resource identification. Nat. Protoc. 15, 1879–1880 (2020).